TG Therapeutics' leukemia drug clears hurdle in key study

(Reuters) - TG Therapeutics Inc said a late-stage study testing a combination of its experimental cancer drug ublituximab and AbbVie Inc's Imbruvica was superior to Imbruvica alone in high-risk patients with a common form of leukemia.